1. Japan Stocks

  2. •

    Healthcare

  3. •

    Medical - Instruments & Supplies
SEED Co.,Ltd.

SEED Co.,Ltd.

7743.T
SEED Co.,Ltd.JP flagTokyo Stock Exchange
511.00
JPY
-3.00
- -
15.47BMarket Cap
SEED Co.,Ltd.
7743.T
(Tokyo Stock Exchange)

Recent

price

511.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
511.08
548.16
650.84
825.25
729.93
852.54
977.21
1,111.59
1,178.01
1,270.01
1,143.18
1,151.87
1,222.12
1,276.54
1,097.99
- -
543.35
Revenue per Share
4.98
8.11
41.94
19.61
8.43
19.24
35.01
47.87
38.5
10.1
45.13
46.09
-12.63
77.4
36.1
- -
37.58
Basic EPS, GAAP
79.31
51.44
1
-15.21
-67.41
136.63
-27.94
-31.09
-67.25
51.66
60.53
85.86
111.33
86.34
-57.61
- -
- -
Free Cash Flow per Basic Share
1.66
1.66
3.31
6.62
8.32
7.49
7.53
9.19
9.17
12
12
11.99
12
11.83
14.99
- -
- -
Dividend per Share
150.49
156.93
195.54
207.36
185.69
197.87
229.87
268.33
296.42
294.53
327.31
356.63
332.01
459.69
406.55
- -
388.47
Book Value per Share
236.17
244.38
283.85
353.34
324.13
308.03
316.76
367.11
375.21
362.83
423.79
425.94
437.13
654.43
576.94
- -
558.46
Tangible Book Value per Share
23
23
23
23
26
26
25
25
25
25
25
25
25
25
30
- -
30
Basic Weighted Avg Shares
11,809
12,666
15,039
19,183
18,733
21,827
24,463
27,827
29,490
31,793
28,618
28,835
30,594
32,397
33,232
33,942
16,449
Sales/Revenue/Turnover
1.85
2.68
5.64
6.04
2.89
4.1
6.21
7.57
6.36
5.45
4.18
4.08
2.06
6.33
4.7
4.24
4.51
Operating Margin (%)
953
918
1,200
1,540
1,561
1,784
1,936
2,148
2,427
2,768
2,838
2,829
2,704
2,830
3,385
3,316
- -
Depreciation Expense
115
187
969
456
216
493
876
1,198
964
253
1,130
1,154
-316
1,964
1,092
1,136
1,138
Net Income, GAAP
15.72
64.48
18.93
56.6
54.85
38.52
32.39
35.39
37.86
59.82
24.23
17.62
- -
5.65
17.04
23.76
23.27
Effective Tax Rate (%)
0.97
1.48
6.44
2.38
1.16
2.26
3.58
4.31
3.27
0.8
3.95
4
-1.03
6.06
3.29
3.35
6.92
Profit Margin (%)
1,175
1,008
1,134
2,448
1,698
708
-1,355
-1,674
-1,161
-2,813
202
922
295
2,756
2,538
-5,843
2,902
Working Capital
3,687
3,540
6,080
5,428
7,029
5,881
6,351
8,234
7,874
7,470
9,539
9,463
7,257
9,275
12,122
12,482
12,551
LT Debt
5,525
5,723
6,645
8,286
8,390
7,952
9,007
10,083
10,999
10,764
11,655
12,532
12,145
17,651
18,385
19,602
17,885
Total Equity
1.42
0.96
4.69
2.87
1.25
2.7
4.65
5.1
3.71
2.03
2.59
2.77
- -
5.09
2.97
2.35
- -
Return on Invested Capital (%)
2.05
2.13
8.44
3.53
1.71
3.35
5.14
5.58
3.85
1.23
3.93
4.02
- -
6.58
3.63
3.56
2.64
Return on Capital (%)
3.34
5.27
23.8
9.76
4.52
10.02
16.2
19.22
13.64
3.42
14.51
13.48
-3.67
19.67
9.11
8.99
11.05
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
ST Debt
15,029
- -
13,926
LT Borrowings
4,894
- -
7,100
LT Finance Leases
4,381
- -
5,452
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
30
- -
30
Market Capitalization
16,597
16,893
15,379

Working Capital

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
Total Current Assets
22,322
- -
20,866
Cash, Cash Equivalents & STI
9,890
- -
8,193
Accounts Receivable, Net
4,429
- -
4,525
Inventories
6,596
- -
6,587
Total Current Liabilities
19,566
- -
17,964
Payables & Accruals
- -
- -
- -
ST Debt
15,029
- -
13,926
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
10.1%
12.11%
6.62%
Free Cash Flow
-34.29%
-38.17%
-61.43%
Net Income, GAAP
-51.92%
-177.42%
3.96%
Sales/Revenue/Turnover
4.71%
3.49%
2.14%
Total Cash Common Dividend
10.21%
10.22%
0.02%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
7,953
7,994
8,182
8,268
32,397
2025
- -
- -
- -
- -
33,232
2026
- -
- -
- -
- -
33,942

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
17.03
- -
- -
- -
77.4
2025
- -
- -
- -
- -
36.1
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
11.83
2025
- -
- -
- -
- -
14.99
2026
- -
- -
- -
- -
- -
Similar Companies
Maxigen Biotech Inc. (1783.TW)
Ingen Technologies, Inc. (IGNT)
PT Maja Agung Latexindo Tbk (SURI.JK)
Safilo Group S.p.A. (SFL.MI)
Sartorius AG (SUVPF)
PlexBio Co., Ltd. (6572.TWO)
Business
SEED Co., Ltd. SEED Co., Ltd. (7743.T) manufactures and sells contact lenses, lens care products, and related ophthalmic items primarily in Japan with international distribution in Asia, Europe, and other regions; the company offers an extensive portfolio of daily disposable soft contact lenses including SEED 1dayPure moisture, SEED 1dayPure moisture for astigmatism, SEED 1dayPure moisture multistage bifocal, SEED 1dayPure EDOF extended depth-of-focus lenses for presbyopia and myopia management, SEED Eye coffret 1day UV, SEED PlusMode 1day Homme, and JILL STUART 1day UV; bi-weekly and monthly replacement lenses such as SEED 2weekPure moisture, SEED 2weekPure moisture multistage bifocal, SEED 2weekPure moisture for astigmatism, SEED MonthlyPure moisture, SEED MonthlyFine UV, and monthly color lens UV; rigid gas permeable lenses; medical contact lenses encompassing orthokeratology and iris varieties; lens care solutions like Forest Leaf EX cleaning solution; eyeglass frames under brands including Vivid Moon, ViVi fleurs, and Plusmix; and pharmaceutical products such as Adeno Test AD adenovirus antigen detection agent. Founded in 1957 and headquartered at 2-40-2 Hongo, Bunkyo-ku, Tokyo, Japan, SEED Co., Ltd. operates manufacturing facilities including the eco-friendly SEED Kounosu laboratory and maintains a workforce of approximately 1,396 employees as of March 2025, with group sales of 33.23 billion yen for the fiscal year ended March 2025. The company targets optometry professionals and consumers seeking high-quality, comfortable vision correction solutions, emphasizing Made-in-Japan production standards for moisture retention, UV protection, and specialized corrections. In recent developments, SEED continues development of smart contact lens platforms in collaboration with partners since 2019 and completed the acquisition of Universal View Co., Ltd. in May 2021 to bolster capabilities, while ongoing innovations like the SEED 1dayPure EDOF—developed with the Brien Holden Vision Institute and validated in 12-month clinical trials—support myopia management and presbyopia treatment amid expanding Asian and European markets.